Effect of treatment on Campylobacter pylori in peptic disease: a randomised prospective trial.
This study investigated the effect of colloidal bismuth subcitrate and cimetidine on Campylobacter pylori in peptic disease. In 74% of 135 patients with peptic disease diagnosed at endoscopy C pylori was detected before treatment. Compared with cimetidine, colloidal bismuth subcitrate significantly decreased the incidence of C pylori after six weeks of treatment (p less than 0.001). In the colloidal bismuth subcitrate group, subsequent healing of the lesion was correlated with the clearance of C pylori, unlike in the cimetidine group. C pylori was strongly associated with the presence of histological gastritis, which was decreased by colloidal bismuth subcitrate (p less than 0.001).
Humphreys
H
H
Department of Clinical Microbiology, St James's Hospital, Dublin, Ireland.
Bourke
S
S
Dooley
C
C
McKenna
D
D
Power
B
B
Keane
C T
CT
Sweeney
E C
EC
O'Moráin
C
C
D000328:Adult; D002169:Campylobacter Infections / Q000150:complications / Q000188:drug therapy*; D002927:Cimetidine / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D004941:Esophagitis / Q000188:drug therapy / Q000209:etiology; D005260:Female; D005756:Gastritis / Q000188:drug therapy / Q000209:etiology; D006801:Humans; D008297:Male; D009942:Organometallic Compounds / Q000627:therapeutic use*; D010437:Peptic Ulcer / Q000188:drug therapy* / Q000209:etiology; D011446:Prospective Studies; D011897:Random Allocation
D009942:Organometallic Compounds; D002927:Cimetidine; C002791:bismuth tripotassium dicitrate